Quinolizidinone M1 receptor positive allosteric modulators
View Patent ↗The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
X 1 CHR 1 ,
wherein R 1 is selected from the group consisting of
(1) hydrogen,
(2) hydroxyl,
(3) —C(═O)—OR 8A , or
(4) —C 1-6 alkyl,
wherein said alkyl is optionally substituted by one or more halogen;
X 2 is CHR 2 , wherein R 2 is hydrogen,
or R 1 and R 2 may be linked together to form a bond or a C 1-2 alkylene, and
the dotted line leading from X 2 represents an optional double bond, provided that when the double bond is present than R 2 is absent;
R 3 is selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —C 6-10 aryl,
(3) heteroaryl group having 5 to 12 ring atoms,
(4) —S(O) m —R 6A ,
(5) hydroxyl,
(6) cyano,
(7) halogen,
(8) —NR 8A —C(═O)—OR 8B
(9) —N(R 9A R 9B ),
wherein said R 3 alkyl, aryl or heteroaryl moiety is optionally substituted with one or more
(a) halogen,
(b) hydroxy,
(c) cyano,
(d) —C 6-10 aryl,
(e) heteroaryl group having 5 to 12 ring atoms,
(f) —C(═O)—OR 6A ,
(g) —O—C 1-6 alkyl,
(h) —C 1-6 alkyl,
(i) —C 3-8 cycloalkyl
(j) —N(R 9A R 9B ),
(k) —S(O) m —R 6A ,
and wherein said alkyl, aryl or cycloalkyl moiety is optionally substituted with one or more
(i) halogen,
(ii) hydroxy,
(iii) cyano,
(iv) —S(O) m —R 6A ,
(v) —C 1-6 alkyl, wherein said alkyl is optionally substituted with fluoro, and
R 4 is selected from the group consisting of
(1) hydrogen,
(2) halogen, and
provided that when the double bond leading from X 2 is present than R 4 is absent,
or R 3 and R 4 are linked together to form a 5-12 membered ring comprising carbon, nitrogen, oxygen or sulfur ring atoms, wherein said ring is optionally substituted with one or more
(1) oxo,
(2) halogen,
(3) cyano,
(4) —C(═O)—OR 8A ,
(5) —O—C 1-6 alkyl,
(6) —C 1-6 alkyl,
(7) —N(R 6A R 6B ), and
(8) —S(O) 2 —R 8A ;
R 5 is selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —(CH 2 ) n -aryl, or
(4) heteroaryl group having 5 to 12 ring atoms,
wherein said R 5 alkyl, aryl or heteroaryl moiety is optionally substituted with one or more
(a) halogen,
(b) hydroxy,
(c) cyano,
(d) —O—C 1-6 alkyl,
(e) —C 1-6 alkyl,
and wherein said alkyl moiety is optionally substituted with one or more
(i) halogen,
(ii) hydroxy,
(iii) cyano,
or R 5 is linked to X 2 to form a —CH 2 — or —CH 2 CH 2 — group;
R 6A and R 6B are independently selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl, and
(3) —(CH 2 ) p -aryl,
wherein said R 6A or R 6B alkyl or aryl moiety is optionally substituted with one or more
(a) halogen,
(b) cyano, and
(c) —O—C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more halo;
R 7 is selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl, and
(3) —CH 2 -aryl,
wherein said R 7 alkyl or aryl moiety is optionally substituted with one or more
(a) halogen,
(b) cyano, and
(c) —O—C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more halo;
R 8A and R 8B are selected from the group consisting of
(1) hydrogen, and
(2) —C 1-6 alkyl;
R 9A and R 9B are independently selected from the group consisting of
(1) hydrogen, or
(2) —C 1-6 alkyl,
wherein said R 9A or R 9B alkyl moiety is optionally substituted with one or more halogen,
or R 9A or R 9B are linked together with the nitrogen to which they are both linked to form a 5 or 6 membered ring comprising carbon, nitrogen, oxygen or sulfur ring atoms, m, n and p are each selected from 0, 1 or 2;
provided that if R 4 is CN, then R 3 is not aryl.
2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or —C 1-3 alkyl.
3. A compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are each CH 2 .
4. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 1 is CHR 1 and X 2 is CHR 2 , and R 1 and R 2 are linked together to form a bond or a C 1-2 alkylene.
5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —C 6-10 aryl, or
(4) heteroaryl group having 5 to 12 ring atoms,
wherein said R 3 alkyl, aryl or heteroaryl moiety is optionally substituted with one or more
(a) halogen,
(b) hydroxy,
(c) cyano,
(d) —C 6-10 aryl,
(e) heteroaryl group having 5 to 12 ring atoms,
(f) —C(═O)—OR 6A ,
(g) —O—C 1-6 alkyl,
(h) —C 1-6 alkyl,
and wherein said alkyl, aryl or heteroaryl moiety is optionally substituted with one or more
(i) halogen,
(ii) hydroxy,
(iii) cyano,
(iv) —S(O) m —R 6A , or
(v) —C 1-6 alkyl, wherein said alkyl is optionally substituted with fluoro.
6. A compound of claims 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of
7. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen.
8. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are linked together to form a 5-12 membered ring comprising carbon, nitrogen, oxygen or sulfur ring atoms, wherein said ring is optionally substituted with one or more
(1) oxo,
(2) halogen,
(3) cyano,
(4) —C(═O)—OR 8A ,
(5) —O—C 1-6 alkyl,
(6) —C 1-6 alkyl,
(7) —N(R 6A R 6B ), and
(8) —S(O) 2 —R 8A .
9. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from the group consisting of
(1) hydrogen,
(2) phenyl, or
(3) heteroaryl group having 5 to 12 ring atoms,
wherein said R 5 phenyl or heteroaryl moiety is optionally substituted with one or more
(a) halogen,
(b) —O—C 1-6 alkyl, or
(c) —C 1-6 alkyl.
10. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from the group consisting of
11. A compound of claim 1 , wherein the compounds of formula (I) are compounds of formula (II):
wherein R 3 and R 5 are as claimed in claim 1 , or a pharmaceutically acceptable salt thereof.
12. A compound of claim 1 , wherein the compounds of formula (I) are compounds of formula (III):
wherein R 3 is as claimed in claim 1 , or a pharmaceutically acceptable salt thereof.
13. A compound of claim 1 , wherein the compounds of formula (I) are compounds of formula (IV):
wherein R 3 is as claimed in claim 1 , and Y is a bond or C 1-2 alkylene, or a pharmaceutically acceptable salt thereof.
14. A compound of claim 1 , wherein the compounds of formula (I) are compounds of formula (V):
wherein R 3 is as claimed in claim 1 , and Y′ is a C 1-2 alkylene, or a pharmaceutically acceptable salt thereof.
15. A compound of claim 1 , which is selected from the group consisting of 4-oxo-1-({4-[4-(trifluoromethyl)phenyl]piperidin-1-yl}methyl)-4H -quinolizine-3-carboxylic acid; 1-{[4-(3,5-difluorophenyl)piperidin-1-yl]methyl}-4-oxo-4H-quinolizine-3-carboxylic acid; 1-{[4-(1-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]methyl}-4-oxo-4H-quinolizine-3-carboxylic acid; 1-[(2-methyl-2,3-dihydro-1H,1′H -spiro[isoquinoline-4,4′-piperidin]-1′-yl)methyl]-4-oxo-4H-quinolizine-3-carboxylic acid; and
1-{[2-(methylsulfonyl)-2,3-dihydro-1H,1′H-spiro[isoquinoline-4,4′-piperidin]-1′-yl]methyl}-4-oxo-4H-quinolizine-3-carboxylic acid;
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.